Stock HLVX HILLEVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News HilleVax, Inc.

Equities

HLVX

US43157M1027

Real-time Estimate Cboe BZX
Other stock markets
 10:34:48 2024-05-23 am EDT 		5-day change 1st Jan Change
13.95 USD -1.34% Intraday chart for HilleVax, Inc. -10.08% -12.77%
May. 22 Hillevax Insider Sold Shares Worth $266,291, According to a Recent SEC Filing MT
May. 09 HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hillevax Insider Sold Shares Worth $266,291, According to a Recent SEC Filing
MT
HilleVax : Corporate Presentation
PU
HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
GL
Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing
MT
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating
MT
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing
MT
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration
MT
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours
MT
HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
GL
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
GL
HilleVax Names New Chief Operating Officer
MT
HilleVax Taps Sean McLoughlin as Chief Operating Officer
DJ
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
GL
HilleVax, Inc. Announces Executive Changes
CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax
MT
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
GL
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLVX Stock
  4. News HilleVax, Inc.